detect
viral
bacteri
dna
nasopharyng
aspir
npa
routin
practic
emerg
case
febril
pneumonia
investig
whether
pneumocysti
jirovecii
dna
could
also
detect
case
conduct
retrospect
screen
consecut
npa
adult
patient
immunocompromis
admit
suspect
pulmonari
infect
influenza
epidem
season
use
realtim
quantit
polymeras
chain
reaction
pcr
assay
pjqpcr
target
p
jirovecii
mitochondri
larg
subunit
ribosom
rna
gene
npa
alreadi
test
respiratori
pathogen
virus
bacteria
found
npa
pjqpcrposit
make
p
jirovecii
fourth
preval
microorgan
screen
eleven
pjqpcrposit
patient
immunocompromis
five
underli
pulmonari
condit
nine
npa
also
posit
anoth
respiratori
pathogen
six
pjqpcrposit
induc
sputa
less
day
npa
procedur
five
diagnos
pneumocysti
pneumonia
four
chronic
lymphoprolif
disord
one
aid
patient
six
avail
pair
quantif
p
jirovecii
dna
show
fewer
copi
npa
induc
sputum
three
pjqpcrneg
npa
correspond
pjqpcrposit
bronchoalveolar
lavag
fluid
underscor
fact
neg
pjqpcr
screen
exclud
diagnosi
pneumocystosi
pneumocysti
pneumonia
pcp
sever
opportunist
infect
caus
pneumocysti
jirovecii
occur
immunocompromis
patient
mainli
posit
human
immunodefici
viru
hiv
low
count
cellsmm
also
frequent
patient
immunocompromis
due
factor
solid
organ
transplant
recipi
patient
haematolog
malign
solid
cancer
receiv
immunosuppress
therapi
autoimmun
inflammatori
diseas
pneumocysti
jirovecii
intrins
restrict
nich
live
surfac
type
pneumocyt
alveoli
bronchoalveolar
lavag
bal
fluid
standard
specimen
use
diagnosi
pcp
bal
sensit
induc
sputum
upper
respiratori
tract
specimen
nasopharyng
aspir
npa
nasal
swab
oral
wash
diagnosi
usual
reli
imag
microscop
detect
although
increas
number
laboratori
current
use
quantit
realtim
polymeras
chain
reaction
qpcr
assay
detect
quantif
p
jirovecii
dna
also
trend
toward
use
less
invas
procedur
npa
instead
lower
respiratori
tract
specimen
induc
sputum
bal
nasopharyng
aspir
alreadi
standard
procedur
detect
viral
bacteri
dna
patient
acut
pneumonia
especi
influenza
season
aim
studi
evalu
valu
ad
p
jirovecii
dna
panel
respiratori
microorgan
adult
patient
present
acut
respiratori
infect
screen
adult
year
patient
suspect
pulmonari
infect
seen
emerg
ward
outpati
clinic
infecti
diseas
depart
saintloui
hospit
februari
march
includ
studi
saintloui
hospit
tertiari
univers
hospit
special
haematolog
renal
transplant
oncolog
npa
collect
use
standard
procedur
word
cathet
insert
patient
nostril
far
posterior
pharynx
mural
vacuum
pump
use
suction
mucos
aspir
collect
steril
tube
use
mucu
extractor
devic
unomed
clayton
australia
sent
microbiolog
laboratori
within
hour
procedur
patient
classifi
immunocompromis
hiv
posit
present
haematolog
malign
solid
tumour
undergon
solid
organ
transplant
highdos
steroid
regimen
mg
per
day
least
day
wherea
patient
classifi
immunocompromis
tabl
result
specif
investig
pcp
occur
within
day
npa
procedur
compar
npa
result
nonintervent
studi
involv
chang
standard
clinic
procedur
biolog
materi
clinic
data
obtain
standard
diagnost
purpos
follow
physician
prescript
note
specif
sampl
clinic
data
anonym
analysi
french
health
public
law
csp
art
state
protocol
type
requir
ethic
approv
exempt
inform
consent
procedur
arriv
laboratori
ml
npa
dilut
ml
phosphat
buffer
salin
one
millilit
mixtur
incub
proteinas
k
hr
c
centrifug
g
min
dna
rna
extract
supernat
use
nuclisenseasymag
autom
system
marci
letoil
franc
elut
final
volum
immedi
revers
trancriptas
step
sampl
test
respiratori
microorgan
includ
assay
pathofind
maastricht
netherland
remain
dnarna
extract
frozen
c
futur
use
assay
use
simultan
detect
result
consid
valid
albumin
dna
copiesml
dna
extract
amplif
yield
assess
use
simplexa
extract
amplif
control
set
focu
diagnost
cypress
calif
usa
intern
control
ic
sum
ic
ad
process
dnarna
extract
quantif
cycl
cq
expect
valid
npa
ic
cq
valu
dnarna
extract
combin
taqman
exogen
intern
posit
control
ipc
dna
appli
biosystem
foster
citi
ca
usa
amplifi
ipc
primer
look
presenc
pcr
inhibitor
extract
dnarna
expect
ipc
cq
second
control
inhous
qpcr
assay
p
jirovecii
pjqpcr
amplifi
bp
fragment
p
jirovecii
mitochondri
largesubunit
lsu
rrna
gene
use
previous
report
thaw
nucleic
acid
extract
result
express
number
base
standard
curv
obtain
plasmid
contain
target
fragment
lsu
gene
describ
elsewher
dilut
factor
estim
initi
npa
quantit
comparison
clinic
sampl
test
duplic
routin
laboratori
detect
p
jirovecii
includ
may
grunwald
giemsa
stain
direct
immunofluoresc
use
monofluokit
p
jirovecii
biorad
hercul
usa
sputum
first
subject
mucolyt
treatment
digesteur
eurobio
courtaboeuf
franc
min
c
sampl
ml
centrifug
rpm
pellet
resuspend
lysi
buffer
dna
extract
use
qiaamp
dna
mini
kit
qiagen
hilden
germani
final
elut
pjqpcr
assay
perform
mean
volum
use
dna
extract
ml
dilut
factor
estim
quantit
comparison
npa
eleven
nucleic
acid
extract
test
ic
cq
valu
test
ipc
reagent
inhibit
detect
exclud
presenc
residu
pcr
inhibitor
kit
result
list
tabl
along
pjqpcr
influenza
virus
b
frequent
detect
microorgan
p
jirovecii
dna
detect
npa
fourth
commonli
found
microorgan
fortytwo
npa
less
albumin
copiesml
one
pjqpcrposit
tabl
patient
sampl
retain
analys
note
pjqpcrposit
sampl
also
posit
microorgan
detect
kit
tabl
microorgan
test
apart
bordetella
pertussi
associ
anoth
microorgan
least
one
sampl
tabl
two
pjqpcrposit
patient
also
test
posit
respiratori
pathogen
cryptococcu
neoforman
mycobacterium
tuberculosi
indic
coinfect
rate
pjqpcr
posit
patient
tabl
one
hundr
ninetyeight
patient
immunocompromis
reflect
patient
popul
univers
hospit
tabl
eleven
pjqpcrposit
patient
known
immun
defici
word
four
pulmonari
condit
copd
asthma
fibrosi
one
known
risk
factor
pcp
p
jirovecii
colonis
tabl
five
pjqpcrposit
patient
chronic
lymphoprolif
disord
word
patient
group
tabl
twentyfour
patient
includ
studi
underw
investig
sputum
bal
within
day
npa
procedur
six
patient
pjqpcrposit
npa
underw
specif
test
p
jirovecii
fungal
load
lower
npa
median
differ
copi
rang
five
six
patient
test
specif
pcp
given
final
diagnosi
pcp
base
clinic
radiolog
evid
tabl
sixth
pjqpcrposit
patient
patient
tabl
test
specif
pcp
diagnos
pcp
given
atovaquon
antipcp
prophylaxi
four
pjqpcrposit
patient
underw
specif
investig
therefor
receiv
diagnosi
pcp
nevertheless
given
antipcp
prophylaxi
tabl
fifteen
patient
pjqpcrneg
npa
underw
investig
pjqpcrneg
sputa
bal
patient
pjqpcrposit
bal
tabl
pneumocysti
jirovecii
qpcr
result
nasopharyng
aspir
npa
neg
microscopi
result
discharg
final
diagnosi
pcp
main
observ
p
jirovecii
dna
detect
npa
adult
patient
seen
febril
pneumonia
flu
season
hospit
p
jirovecii
fourth
preval
respiratori
pathogen
assess
influenza
virus
b
preval
comparison
previou
studi
difficult
patient
select
basi
bal
result
focus
children
test
base
dna
detect
rais
issu
mean
posit
result
extent
observ
symptom
attribut
relev
agent
particularli
sever
pathogen
detect
simultan
typic
immunocompromis
host
pjqpcrposit
sampl
addit
respiratori
microorgan
detect
patient
nevertheless
preval
p
jirovecii
dna
sampl
interpret
incident
observ
eleven
pjqpcrposit
belong
popul
risk
pcp
patient
aid
haematolog
malign
solid
tumor
renal
transplant
receiv
highdos
steroid
therapi
risk
factor
colon
chronic
obstruct
pulmonari
diseas
also
present
tabl
interpret
term
colon
disput
patient
symptomat
febril
pneumonia
retrospect
design
studi
preclud
calcul
sensit
specif
npa
detect
p
jirovecii
dna
patient
undergo
diagnost
workup
particular
systemat
analysi
sputum
initi
goal
detect
virus
diagnost
workup
perform
six
patient
basi
clinic
suspicion
five
receiv
final
diagnosi
pcp
basi
microscop
observ
fungu
practic
point
view
three
argument
made
ad
p
jirovecii
panel
microorgan
test
case
febril
pneumonia
first
demonstr
npa
screen
could
use
trigger
invas
investig
patient
risk
pcp
altern
clinic
suspicion
radiolog
sign
patient
background
might
consid
suffici
basi
initi
treatment
antipcp
drug
second
pjqpcrposit
npa
could
use
support
antipcp
drug
prophylaxi
sometim
restrain
due
potenti
side
effect
trimethoprimsulfamethoxazol
third
author
suggest
without
intervent
fullblown
pcp
like
occur
within
month
pjqpcrposit
result
one
limit
test
npa
p
jirovecii
dna
present
smaller
quantiti
lower
respiratori
specimen
strict
quantit
comparison
problemat
given
heterogen
volum
consist
clinic
specimen
howev
case
observ
fewer
dna
copi
npa
sampl
sampl
p
jiroveciiposit
npa
may
therefor
correspond
much
higher
fungal
load
alveoli
threshold
appli
bal
appli
npa
note
three
patient
p
jirovecii
dna
copyml
npa
diagnos
pcp
moreov
npa
contain
minimum
number
human
cell
avoid
fals
neg
result
viru
aspergillu
detect
therefor
exclud
possibl
npa
fals
neg
p
jirovecii
fungal
load
consider
underestim
poor
qualiti
npa
three
pjqpcrneg
npa
correspond
pjqpcrposit
bal
fluid
indic
neg
npa
use
exclud
pcp
util
detect
p
jirovecii
dna
npa
would
greatli
improv
combin
noninvas
test
detect
betadglucan
serum
detect
p
jirovecii
dna
serum
conclus
suggest
would
worthwhil
includ
p
jirovecii
panel
respiratori
pathogen
assess
adult
case
febril
pneumonia
particularli
immunocompromis
patient
would
incur
limit
addit
cost
nucleic
acid
alreadi
extract
test
pjqpcrposit
result
prompt
discuss
specif
investig
therapi
high
probabl
pcp
find
also
confirm
outsid
context
flu
epidem
